Natural Chromium Picolinate- this ingredient helps you control hunger and food cravings. Additionally, it makes your system ...

On Wednesday May 14, people from across Ontario will be heading into the Ontario Legislature for a “Day of Action” to ask the Ford government to stop closing their local hospitals and to provide the ...

ATH-1105 is the Company’s novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential ...

Comprehensive Healthcare began offering same-day access to mental health assessments in 2023, eliminating the need for appointments and adopting a walk-in format. In the year following its ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients ...

The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite. Plan to ...

Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) ...

The presentation will highlight how data from patients treated with IL-2 and IL-12 INDUKINE molecules in first-in-human clinical trials have successfully validated Werewolf’s unique approach to ...

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the ...

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, ...

The DBA/2 mouse model is an inbred mouse strain in which young DBA/2 mice are susceptible to audiogenic seizures, making them a model for epilepsy studies. This epilepsy model does re-capitulate ...

The abstracts being presented at ASGCT 2025 capture the outcome of efforts to advance Tenaya’s core capabilities in novel capsid engineering, identification, design and optimization of ...